MedTrace Logo

Patient Preference Study in Type-2 Diabetes Mellitus: Discrete Choice Experiment (DCE) to Support Novo Nordisk's Long-Acting Insulin

NCT06592950 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 513

Last updated 2024-09-19

No results posted yet for this study

Summary

The primary objective of this research is to assess T2DM patient preferences for a once weekly insulin treatment. The study involves a qualitative interview phase and quantitative survey phase with a Discrete Choice Experiment (DCE).

Conditions

  • Type-2 Diabetes Mellitus (T2DM)

Interventions

OTHER

No treatment given

Online survey

OTHER

No treatment given

Interviews

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency dept. 2834 · Novo Nordisk A/S

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-02
Primary Completion
2024-04-29
Completion
2024-04-29

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06592950 on ClinicalTrials.gov